Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

@article{Schwaederl2015PrecisionOT,
  title={Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.},
  author={Maria C Schwaederl{\'e} and Barbara A Parker and Richard B. Schwab and Gregory A. Daniels and David E Piccioni and Santosh Kesari and Teresa L. Helsten and Lyudmila Bazhenova and Julio Romero and Paul Timothy Fanta and Scott Michael Lippman and Razelle Kurzrock},
  journal={Molecular cancer therapeutics},
  year={2015},
  volume={15 4},
  pages={
          743-52
        }
}
By profiling their patients' tumors, oncologists now have the option to use molecular results to match patients with drug(s) based on specific biomarkers. In this observational study, 347 patients with solid advanced cancers and next-generation sequencing (NGS) results were evaluated. Outcomes for patients who received a "matched" versus "unmatched" therapy following their NGS results were compared. Eighty-seven patients (25%) were treated with a "matched" therapy, 93 (26.8%) with an "unmatched… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Impact of a biomarker-based strategy on oncology drug development: ameta-analysis of clinical trials leading to FDA approval

  • JardimDL Fontes, M Schwaederle, C Wei, JJ Lee, DS Hong, AM Eggermont
  • J Natl Cancer Inst ;107
  • 2015
1 Excerpt

Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials

  • SchwaederleM, ZhaoM, JJ Lee, AM Eggermont, RL Schilsky, J Mendelsohn
  • J Clin Oncol ;33:3817–25
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…